<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545127</url>
  </required_header>
  <id_info>
    <org_study_id>000050</org_study_id>
    <nct_id>NCT02545127</nct_id>
  </id_info>
  <brief_title>Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely</brief_title>
  <acronym>MERMAID</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Exploring the Efficacy and Safety of Intra-nasal Administration of Merotocin in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction and support of lactation in women with preterm delivery and inadequate milk
      production.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of mother's own milk (MoM)</measure>
    <time_frame>Daily days 1 to 14</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of daily volume of MoM ≥ 500 mL</measure>
    <time_frame>From randomization (Day 1) to Day 14</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of daily volume of MoM ≥ 750 mL</measure>
    <time_frame>From randomization (Day 1) to Day 14</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a daily volume of MoM ≥ 500 mL</measure>
    <time_frame>Days 1 to 14</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a daily volume of MoM ≥ 750 mL</measure>
    <time_frame>Days 1 to 14</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of MoM</measure>
    <time_frame>Days 15 to 17</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of MoM fed to the infant</measure>
    <time_frame>Days 1 to 14</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of formula/donor milk fed to the infant</measure>
    <time_frame>Days 1 to 14</time_frame>
    <description>Measured by weight in grams converted to volume in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merotocin concentration in milk</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merotocin concentration in milk</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infant body weight</measure>
    <time_frame>From baseline (Day 1) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and intensity of adverse events (AEs) in maternal participants</measure>
    <time_frame>From screening (0-96 hours of delivery) up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and intensity of AEs in infants</measure>
    <time_frame>From screening until milk expressed Days 1-14 is consumed/discarded or infant discharged from neonatal intensive care unit (NICU), whichever occurs last.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in routine safety laboratory parameters in maternal participants</measure>
    <time_frame>From screening up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of maternal participants with markedly abnormal changes in laboratory values</measure>
    <time_frame>From screening up to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preterm Delivery</condition>
  <condition>Inadequate Milk Production</condition>
  <arm_group>
    <arm_group_label>Merotocin (a selective oxytocin-receptor agonist)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Merotocin</intervention_name>
    <description>Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).</description>
    <arm_group_label>Merotocin (a selective oxytocin-receptor agonist)</arm_group_label>
    <other_name>FE 202767</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Delivered at hospital associated with trial center

          -  Delivered preterm singleton gestational age 24 weeks + 0 days to 31 weeks + 6 days

          -  Willing to express milk 6 to 8 times/24 hours

          -  Produced &lt; 200 mL milk in 24 hours prior to randomization

          -  Delivered 96 to 144 hours prior to randomization

        Exclusion Criteria:

          -  Pre-pregnancy body mass index (BMI) &gt; 40 kg/m^2

          -  Mastitis

          -  History of breast trauma, breast surgery, nipple piercing

          -  Prolactin-releasing pituitary tumor, history of Sheehan's syndrome, pituitary
             surgery/radiation therapy

          -  Pre-pregnancy insulin-dependent diabetes mellitus, polycystic ovarian syndrome

          -  Unstable thyroid disease

          -  Moderate or severe renal or hepatic impairment

          -  Mental illness

          -  Significant nasal congestion or mucous production

          -  Use of anti-psychotic drugs within past 12 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC) - Children's Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inadequate milk production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

